InspireMD Inc. (NSPR)

InspireMD, Inc. (NSPR) stock has declined by 35.09% between January 13, 2025, and January 9, 2026, with a -34.420% change over the past year. Key events include the January 12, 2026, publication of the C-GUARDIANS Pivotal Trial Manuscript in JACC, the November 24, 2025, publication of the Landmark CREST-2 Study in the New England Journal of Medicine, and the November 24, 2025, appointment of Dan Dearen to its Board of Directors. On November 4, 2025, InspireMD reported its Third Quarter 2025 financial results, with total revenue increasing by 39% year-over-year to $2.5 million, but a wider net loss of $12.7 million. Inducement grants for new non-executive employees were announced on October 8, 2025, and November 21, 2025, and the Q2 2025 Earnings Release occurred on August 5, 2025.

Information regarding specific demand seasonality patterns for InspireMD, Inc.'s products and services is available through financial analysis tools that display mean and median monthly returns to identify seasonal trends. However, the detailed seasonal patterns are not explicitly provided in the available search results.

InspireMD, Inc. is a medical device company focused on developing and commercializing products for treating carotid artery and other vascular diseases. The company's core technology is the MicroNet® stent platform, a nanostructured mesh designed to prevent embolic events during stent implantation. Its major products include the CGuard® Carotid Embolic Prevention System (EPS), CGuard Prime Stent System, SwitchGuard Neuroprotection System, and MGuard Prime Embolic Protection System (MGuard Prime EPS).

InspireMD, Inc. has a global presence, focusing on Europe, Latin America, the Middle East, and the Asia Pacific, including countries like Italy, Germany, and Russia. The company has achieved double-digit market share in over 30 countries internationally. The U.S. commercial launch of its CGuard Prime system has been initiated. The company is headquartered in Miami, Florida, United States.

InspireMD's brand reputation has been positively influenced by the publication of the C-GUARDIANS pivotal trial manuscript in the Journal of the American College of Cardiology (JACC) in January 2026, and the landmark CREST-2 Study in the New England Journal of Medicine in November 2025. The company's mission to prevent stroke and improve patient outcomes, along with the CGuard Prime's MicroNet™ mesh technology demonstrating superior clinical data, further bolsters its reputation for safety and efficacy.

InspireMD, Inc. is significantly owned by institutional shareholders, who hold 53.65% of the stock, and insiders, who own 59.30%. Major institutional owners include Rosalind Advisors Inc., Nantahala Capital Management LLC, Standard Life Aberdeen plc, Parkman Healthcare Partners LLC, Velan Capital Investment Management LP, OrbiMed Advisors LLC, Marshall Wace, LLP, Soleus Capital Management, L.P., Ghisallo Capital Management LLC, and Pura Vida Investments, Llc. The largest individual shareholder is Ofir Paz, who owns 10.26 million shares, representing 24.22% of the company.